DEFA14A: Anteris Postpones Special Stockholder Meeting

Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders to September 11, 2025, to allow for broader stockholder participation.

Summary

• Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders, originally scheduled for September 4, 2025.
• The meeting is now scheduled to be held virtually on Thursday, September 11, 2025, at 5:00 p.m. Central time (8:00 a.m. AEST on Friday, September 12, 2025).
• The record date for the Special Meeting, August 11, 2025, remains unchanged.
• The postponement aims to provide stockholders with additional time to vote and facilitate broader participation.
• The Board of Directors unanimously recommends voting FOR the proposals outlined in the definitive Proxy Statement filed on August 18, 2025.
• Existing votes will remain valid, and new voting deadlines are set for September 10, 2025, for common stock and September 9, 2025, for CDIs.

Sentiment

Score: 6

Explanation: The postponement is for a positive reason (broader participation), indicating a commitment to good governance, but it is still a delay in an administrative process. The unanimous board recommendation is a positive sign of internal alignment.

Positives

• The postponement aims to facilitate broader stockholder participation, enhancing corporate governance and engagement.
• The Board of Directors unanimously recommends voting FOR the proposals, indicating internal alignment on the matters to be voted upon.

Negatives

• The Special Meeting has been postponed, causing a slight delay in the company's administrative processes.

Risks

• Uncertainties related to the presence of a quorum at the Special Meeting.
• Uncertainties related to the receipt of stockholder approval of the proposals presented at the Special Meeting.
• General risks described in Anteris' Annual Report on Form 10-K filed March 12, 2025 (as amended April 29, 2025) and Quarterly Reports on Form 10-Q filed May 13, 2025, and August 11, 2025.

Future Outlook

The company acknowledges uncertainties regarding achieving a quorum at the Special Meeting and securing stockholder approval for the presented proposals. It does not assume any obligation to update forward-looking statements to conform to actual results or revised expectations, except as required by law.

Management Comments

• The Company's Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company's definitive Proxy Statement for the Special Meeting.

Industry Context

This administrative update does not directly relate to broader industry trends in the structural heart medical device sector. Anteris continues its work in designing, developing, and commercializing medical devices like the DurAVR Transcatheter Heart Valve for aortic stenosis, utilizing its ADAPT tissue technology, which has a decade of clinical use.

Corporate Governance

Stakeholder Impact

• Shareholders: Provided additional time to vote, potentially increasing participation and ensuring their voices are heard on proposals.

Next Steps

• Stockholders to submit votes by the new deadlines (September 9, 2025, for CDIs; September 10, 2025, for common stock).
• Hold the Special Meeting of Stockholders virtually on September 11, 2025.

Key Dates

Keywords

Anteris Technologies, AVR, SEC Filing, Proxy Statement, Stockholder Meeting, Corporate Governance, Voting, Medical Devices, Structural Heart, DurAVR THV